Biomea Fusion, Inc. (BMEA) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-47.19M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.45× | Operating cash flow / net income. Period ending 2026-06-30. $-47.19M ÷ $-32.54M ≈ 1.45× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -47.19M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -32.54M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-47.19M | (m) | (m) | (m) | (m) | $-32.54M | (m) | (m) | (m) | 1.45× |
| 2026-03-31 | (m) | (m) | $-56.37M | (m) | (m) | (m) | (m) | $-44.95M | (m) | (m) | (m) | 1.25× |
| 2025-12-31 | (m) | (m) | $-70.37M | (m) | (m) | (m) | (m) | $-61.80M | (m) | (m) | (m) | 1.14× |
| 2025-09-30 | $-86.52M | (m) | $-86.43M | $82.00K | (m) | (m) | (m) | $-95.71M | (m) | (m) | (m) | 0.90× |
| 2025-06-30 | $-100.37M | (m) | $-100.10M | $268.00K | (m) | (m) | (m) | $-112.09M | (m) | (m) | (m) | 0.89× |
| 2025-03-31 | $-113.86M | (m) | $-113.53M | $327.00K | (m) | (m) | (m) | $-128.63M | (m) | (m) | (m) | 0.88× |
| 2024-12-31 | $-120.26M | (m) | $-119.89M | $362.00K | (m) | (m) | (m) | $-138.43M | (m) | (m) | (m) | 0.87× |
| 2024-09-30 | $-113.02M | (m) | $-112.73M | $288.00K | (m) | (m) | (m) | $-144.01M | (m) | (m) | (m) | 0.78× |
| 2024-06-30 | $-111.55M | (m) | $-111.41M | $141.00K | (m) | (m) | (m) | $-139.65M | (m) | (m) | (m) | 0.80× |
| 2024-03-31 | $-105.08M | (m) | $-104.58M | $499.00K | (m) | (m) | (m) | $-127.27M | (m) | (m) | (m) | 0.82× |
| 2023-12-31 | $-99.96M | (m) | $-96.59M | $3.37M | (m) | (m) | (m) | $-117.25M | (m) | (m) | (m) | 0.82× |
| 2023-09-30 | $-98.03M | (m) | $-93.96M | $4.07M | (m) | (m) | (m) | $-107.69M | (m) | (m) | (m) | 0.87× |
| 2023-06-30 | $-90.84M | (m) | $-86.85M | $3.98M | (m) | (m) | (m) | $-102.15M | (m) | (m) | (m) | 0.85× |
| 2023-03-31 | $-80.31M | (m) | $-76.47M | $3.84M | (m) | (m) | (m) | $-94.51M | (m) | (m) | (m) | 0.81× |
| 2022-12-31 | $-63.45M | (m) | $-62.42M | $1.03M | (m) | (m) | (m) | $-81.83M | (m) | (m) | (m) | 0.76× |
| 2022-09-30 | $-58.73M | (m) | $-58.12M | $611.00K | (m) | (m) | (m) | $-71.22M | (m) | (m) | (m) | 0.82× |
| 2022-06-30 | $-53.01M | (m) | $-50.31M | $2.70M | (m) | (m) | (m) | $-60.94M | (m) | (m) | (m) | 0.83× |
| 2022-03-31 | $-44.56M | (m) | $-41.36M | $3.20M | (m) | (m) | (m) | $-52.08M | (m) | (m) | (m) | 0.79× |
| 2021-12-31 | $-38.61M | (m) | $-35.44M | $3.17M | (m) | (m) | (m) | $-41.57M | (m) | (m) | (m) | 0.85× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-4.51M | (m) | $-4.46M | $51.00K | (m) | (m) | (m) | $-5.32M | (m) | (m) | (m) | 0.84× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $-1.28M | (m) | (m) | (m) | (m) | $-1.20M | (m) | (m) | (m) | 1.07× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |